Form 4: Apimeds Grants Stock Options to Chairman & CMO Kim

Apimeds Pharmaceuticals US, Inc. granted 3,000 stock options to Chairman and CMO Christopher Kim, exercisable at $1.92, with vesting contingent on continued service and stockholder approval.

Summary

• Christopher Kim, Chairman and CMO of Apimeds Pharmaceuticals US, Inc. (APUS), was granted 3,000 stock options.
• The options have an exercise price of $1.92 per share.
• The transaction date for the grant was October 15, 2025.
• The options expire on October 15, 2035.
• Vesting occurs in quarterly installments beginning October 1, 2025, with full vesting after three years, subject to continued service.
• Full vesting will also occur upon a Change in Control as defined in the company's incentive plan.
• The options are not exercisable until stockholder approval is obtained to amend the incentive plan to increase the number of shares available for issuance.

Sentiment

Score: 6

Explanation: The grant of stock options is a positive for executive retention and alignment, but the contingency on stockholder approval and potential future dilution introduce minor uncertainties.

Positives

• The grant of stock options aligns management's interests with shareholder value creation, incentivizing long-term performance.
• The vesting schedule encourages retention of key executive talent over a three-year period.
• The 'Change in Control' clause provides an incentive for management during potential acquisition scenarios.

Negatives

• The exercisability of the options is contingent on future stockholder approval, introducing uncertainty.
• The need for stockholder approval to increase shares for the incentive plan suggests potential future dilution for existing shareholders.

Risks

• Shareholder Dilution Risk: Stockholder approval to increase shares for the incentive plan could lead to dilution of existing shareholders' ownership percentage.
• Contingency Risk: The options are not exercisable until stockholder approval is obtained for an amendment to the incentive plan, which may not be granted or could be delayed.
• Retention Risk: Vesting is subject to continued service, meaning the company could lose the incentive if the executive departs before full vesting.

Future Outlook

The future exercisability of these stock options is contingent upon obtaining stockholder approval to amend the company's incentive plan to increase the number of shares available for issuance. Vesting will occur over three years, subject to continued service, or immediately upon a Change in Control.

Management Comments

• The shares of common stock subject to the option shall vest in quarterly installments beginning October 1, 2025, such that the award shall be fully vested after three years subject to the reporting person's service to the issuer continuing through and on each vesting date. This option is not exercisable until stockholder approval is obtained to approve an amendment to the issuer's incentive plan (the 'Plan') to increase the number of shares of common stock available for issuance under the Plan. The shares of common stock subject to the option shall vest in full upon the occurrence of a Change in Control, as defined in the Plan.

Industry Context

The grant of stock options to key executives is a standard practice in the pharmaceutical and biotechnology industries to attract, retain, and incentivize leadership, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The grant of 3,000 stock options to Christopher Kim, who serves as Director, Chairman, and CMO, constitutes a related party transaction as it involves a key executive and the company.

Stakeholder Impact

• Shareholders: Potential for future dilution if the incentive plan amendment is approved and options are exercised. However, the grant aims to align management's interests with shareholder value creation.
• Employees (specifically Christopher Kim): Receives a significant long-term incentive, contingent on performance and continued service, enhancing retention.

Next Steps

• The company will need to seek stockholder approval for an amendment to its incentive plan to increase the number of shares available for issuance.
• Christopher Kim's options will begin vesting in quarterly installments from October 1, 2025, subject to continued service.

Key Dates

Keywords

Apimeds Pharmaceuticals, APUS, Christopher Kim, Stock Options, Executive Compensation, Form 4, SEC Filing, Corporate Governance, Incentive Plan, Shareholder Approval